CERo Therapeutics escalates CER-1236 Phase 1 trial to 10 million cells/kg cohort

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings, Inc. - Common Stock

CERO

0.00
  • Cero Therapeutics completed dosing and 28-day safety follow-up for second ascending-dose cohort in Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
  • Safety profile remained supportive of continued escalation, with no dose-limiting toxicities reported in this cohort.
  • Prior interim safety observations were presented at Tandem Meetings in February, showing no severe treatment-related safety signals during dose-limiting toxicity monitoring.
  • Enrollment has started for next higher-dose cohort, expected to expand patient mix to include myelodysplastic syndrome and myelofibrosis, broadening commercial and clinical positioning beyond initial acute myeloid leukemia focus.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110815PRIMZONEFULLFEED9716664) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.